Consistent with our findings, we also found aberrant promoter methylation of FBXO32, but the discordant result was that FBXO32 was hypomethylated and highly expressed in PanIN and PDAC, in comparison to normal tissues, as well as closely relevant in cell stemness, tumor size, lymphatic metastasis, tumor differentiation, tumor staging, and the prognosis of PDAC patients. This evidence concerns the gene FBXO32 and neoplasm.